New and emerging therapies for sepsis

Area of Science:

• Sepsis pathophysiology and treatment.
• Critical care medicine.
• Pharmacological interventions for sepsis.

Background:

• Sepsis involves dysregulated inflammation, increased coagulation, and diminished fibrinolysis.
• Imbalances in these systems lead to coagulopathy, thrombosis, organ failure, and death.
• Understanding sepsis mechanisms is crucial for developing effective therapies.

Purpose of the Study:

• Review recent advances in sepsis pathophysiology.
• Evaluate the rationale for drotrecogin alfa and other sepsis agents in clinical trials.
• Provide an overview of current and investigational sepsis treatments.

Main Methods:

• Conducted a MEDLINE search (1990-2001) for sepsis pathophysiology and treatment literature.
• Supplemented with AdisInsight database using relevant search terms.
• Reviewed clinical efficacy studies of drotrecogin alfa and other Phase III agents.

Main Results:

• Sepsis pathophysiology involves a complex interplay of coagulation, fibrinolysis, and inflammation.
• Drotrecogin alfa (activated protein C) has anticoagulant, profibrinolytic, and anti-inflammatory properties.
• Several agents, including drotrecogin alfa, are in late-stage clinical development for severe sepsis.

Conclusions:

• The approval of drotrecogin alfa marks a significant step in sepsis management.
• New therapeutic strategies offer renewed optimism for reducing sepsis-associated mortality.
• Continued research into sepsis pathophysiology is vital for further treatment advancements.